Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
Holding ICCM?
Track your performance easily
ICCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $1.57
Previous CloseN/A
Volume318.06K
Average Volume (3M)462.23K
Market Cap
$70.15M
Enterprise ValueN/A
Total Cash (Recent Filing)$11.26M
Total Debt (Recent Filing)$281.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Feb 03, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding56,569,000
10 Day Avg. Volume329,501
30 Day Avg. Volume462,234
Standard Deviation1.01
R-Squared0.02
Alpha0.12
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.37Price Target Upside173.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Icecure Medical News
PremiumCompany Announcements
IceCure Medical Seeks to Expand in China with ProSense® Cryoablation System
PremiumCompany Announcements
Icecure Medical Announces Equity Distribution AgreementPremiumCompany Announcements
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025
PremiumCompany Announcements
IceCure Medical Regains Nasdaq Compliance, Securing Market Position
Bulls Say, Bears Say
Bulls Say
Market GrowthICCM's inline 3Q24 performance and increased sales of the ProSense system and its disposable probes reflect growing adoption and utilization, signaling strong growth potential in the medical device market.
Regulatory ApprovalThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System for the treatment of early-stage low-risk invasive breast cancer, indicating a high likelihood of FDA approval.
Technological AdvancementIceCure received marketing authorization from the FDA for the next-generation XSense single probe cryoablation system, further validating the company’s cryoablation platform technology and strengthening market penetration of minimally invasive treatments.
Bears Say
Financial StabilityThe company may need to raise additional capital within the next 12 months.
Regulatory And Commercial RisksRisks include failure of cryoablation systems in clinical trials, failure to secure regulatory approval, failure to achieve commercial success, and dilution risk.
Revenue PerformanceRevenue estimates for 2024 and 2025 have been lowered, despite fine-tuning GAAP loss per share estimates.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.07% Other Institutional Investors
99.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.48 and its highest was $1.57 in the past 12 months.
What is IceCure Medical’s market cap?
IceCure Medical’s market cap is $70.15M.
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Feb 03, 2025 which is in 3 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on Nov 26, 2024. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.075 by -$0.005.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -0.08.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 56,569,000 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.075. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of IceCure Medical?
Currently, no hedge funds are holding shares in ICCM
---
Icecure Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.37 (173.98% Upside)
$3.37 (173.98% Upside)
Blogger Sentiment
Bullish
ICCM Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.48%
12-Months-Change
Fundamentals
Return on Equity
-111.35%
Trailing 12-Months
Asset Growth
-21.33%
Trailing 12-Months
Company Description
IceCure Medical
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women's health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
---
ICCM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in sales and improved financial metrics, driven by increased adoption of ProSense and upcoming catalysts, including potential FDA approval. However, challenges remain, including a significant net loss, decreased revenue recognition in Japan, and some uncertainty regarding FDA approval timing.Read More>---
ICCM Stock 12 Month Forecast
Average Price Target
$3.37
▲(173.98% Upside)
Technical Analysis
Best Analysts Covering ICCM
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+11.84%
reiterated a buy rating 2 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +11.84% per trade.
---